Drug review: Carfilzomib
Carfilzomib is a second generation proteasome inhibitor approved for use in relapsed/ refractory multiple myeloma. The mechanism of action, usage, toxicity and key trials involving this agent are briefly reviewed here.
Zapisane w:
| 1. autor: | |
|---|---|
| Format: | Artigo |
| Język: | Inglês |
| Wydane: |
Thieme Medical and Scientific Publishers Pvt. Ltd.
2019-01-01
|
| Seria: | Indian Journal of Medical and Paediatric Oncology |
| Hasła przedmiotowe: | |
| Dostęp online: | http://www.ijmpo.org/article.asp?issn=0971-5851;year=2019;volume=40;issue=1;spage=130;epage=131;aulast=Ganesan |
| Etykiety: |
Nie ma etykietki, Dołącz pierwszą etykiete!
|